CA2457894C - Analysis of circulating tumor cells, fragments, and debris - Google Patents

Analysis of circulating tumor cells, fragments, and debris Download PDF

Info

Publication number
CA2457894C
CA2457894C CA2457894A CA2457894A CA2457894C CA 2457894 C CA2457894 C CA 2457894C CA 2457894 A CA2457894 A CA 2457894A CA 2457894 A CA2457894 A CA 2457894A CA 2457894 C CA2457894 C CA 2457894C
Authority
CA
Canada
Prior art keywords
cells
analysis
cell
ctc
ctcs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2457894A
Other languages
English (en)
French (fr)
Other versions
CA2457894A1 (en
Inventor
Galla Chandra Rao
Christopher Larson
Madeline Repollet
Herman Rutner
Leon Terstappen
Shawn Mark O'hara
Steven Gross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Diagnostics LLC
Original Assignee
Veridex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26979228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2457894(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Veridex LLC filed Critical Veridex LLC
Publication of CA2457894A1 publication Critical patent/CA2457894A1/en
Application granted granted Critical
Publication of CA2457894C publication Critical patent/CA2457894C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/549—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic with antigen or antibody entrapped within the carrier
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA2457894A 2001-08-23 2002-08-23 Analysis of circulating tumor cells, fragments, and debris Expired - Fee Related CA2457894C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31415101P 2001-08-23 2001-08-23
US60/314,151 2001-08-23
US36962802P 2002-04-03 2002-04-03
US60/369,628 2002-04-03
PCT/US2002/026861 WO2003019141A2 (en) 2001-08-23 2002-08-23 Analysis of circulating tumor cells, fragments, and debris

Publications (2)

Publication Number Publication Date
CA2457894A1 CA2457894A1 (en) 2003-03-06
CA2457894C true CA2457894C (en) 2014-07-08

Family

ID=26979228

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2457894A Expired - Fee Related CA2457894C (en) 2001-08-23 2002-08-23 Analysis of circulating tumor cells, fragments, and debris
CA2457891A Expired - Fee Related CA2457891C (en) 2001-08-23 2002-08-23 Method of preservation of circulating tumor cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2457891A Expired - Fee Related CA2457891C (en) 2001-08-23 2002-08-23 Method of preservation of circulating tumor cells

Country Status (11)

Country Link
EP (2) EP1425294B2 (https=)
JP (3) JP2005501236A (https=)
KR (2) KR20040030984A (https=)
CN (2) CN1596265A (https=)
AT (1) ATE401574T1 (https=)
AU (2) AU2008288601B2 (https=)
BR (2) BR0212125A (https=)
CA (2) CA2457894C (https=)
DE (1) DE60227678D1 (https=)
IL (2) IL160209A0 (https=)
WO (2) WO2003019141A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079212A1 (en) * 2015-11-04 2017-05-11 Axon Dx, Llc Cell detection, capture, analysis, aggregation, and output methods and apparatus

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863012B2 (en) 2004-02-17 2011-01-04 Veridex, Llc Analysis of circulating tumor cells, fragments, and debris
WO2003019141A2 (en) * 2001-08-23 2003-03-06 Immunivest Corporation Analysis of circulating tumor cells, fragments, and debris
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
JP4496407B2 (ja) 2002-05-13 2010-07-07 ベクトン・ディキンソン・アンド・カンパニー プロテアーゼ阻害剤試料採取システム
EP2359689B1 (en) 2002-09-27 2015-08-26 The General Hospital Corporation Microfluidic device for cell separation and use thereof
CA2445204C (en) 2002-10-16 2014-08-12 Streck Laboratories, Inc. Method and device for collecting and preserving cells for analysis
CA2516795C (en) 2003-02-27 2013-01-15 Immunivest Corporation Circulating tumor cells (ctc's): early assessment of time to progression,_survival and response to therapy in metastatic cancer patients
CA2539108A1 (en) * 2003-09-18 2005-03-31 Immunivest Corporation Operator independent programmable sample preparation and analysis system
EP1861509B1 (en) * 2005-03-14 2015-09-09 Janssen Diagnostics, LLC A method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells
US20070196820A1 (en) 2005-04-05 2007-08-23 Ravi Kapur Devices and methods for enrichment and alteration of cells and other particles
DK2500439T4 (da) 2005-06-20 2017-11-13 Advanced Cell Diagnostics Inc Kits og produkter til detektering af nukleinsyrer i individuelle celler og til identifikation af sjældne celler fra store heterogene cellepopulationer
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
WO2011050103A1 (en) * 2009-10-21 2011-04-28 The Scripps Research Institute Method of using non-rare cells to detect rare cells
US8337755B2 (en) 2006-03-13 2012-12-25 Veridex, Llc Operator independent programmable sample preparation and analysis system
NZ573187A (en) * 2006-06-02 2011-11-25 Pfizer Prod Inc Circulating tumor cell assay for predicting efficacy of 1gf-1r antagonist therapy
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
EP2029779A4 (en) 2006-06-14 2010-01-20 Living Microsystems Inc HIGHLY PARALLEL SNP GENOTYPING UTILIZATION FOR FETAL DIAGNOSIS
EP2041299A4 (en) 2006-07-14 2010-01-13 Aviva Biosciences Corp METHOD AND COMPOSITIONS FOR DETECTION OF RARE CELLS FROM A BIOLOGICAL SAMPLE
BRPI0807384A2 (pt) * 2007-02-27 2014-05-20 Sentoclone Ab Método de uma etapa para detecção direta ou simultânea de uma célula cancerosa ou elemento de célula cancerosa em uma amostra biológica, kit para uso em um método, base de dados, método para indetificar células cancerosas, e, uso de uma base de dados.
GB2461476B (en) * 2007-04-16 2012-02-22 Immunivest Corp A rapid, semi-automated method to detect respiratory virus infected cells in direct specimens
US8003314B2 (en) 2007-04-16 2011-08-23 Diagnostic Hybrids, Inc. Methods for direct fluorescent antibody virus detection in liquids
US8110101B2 (en) 2007-08-30 2012-02-07 Veridex, Llc Method and apparatus for imaging target components in a biological sample using permanent magnets
US7828968B2 (en) 2007-08-30 2010-11-09 Veridex, Llc Method and apparatus for imaging target components in a biological sample using permanent magnets
EP2229441B1 (en) 2007-12-12 2014-10-01 The Board of Trustees of The Leland Stanford Junior University Method and apparatus for magnetic separation of cells
CA3069082C (en) 2008-09-20 2022-03-22 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US11634747B2 (en) 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
NO2398912T3 (https=) 2009-02-18 2018-02-10
WO2011038403A1 (en) 2009-09-28 2011-03-31 Yuling Luo Methods of detecting nucleic acid sequences with high specificity
US20130171621A1 (en) 2010-01-29 2013-07-04 Advanced Cell Diagnostics Inc. Methods of in situ detection of nucleic acids
WO2011099565A1 (ja) * 2010-02-10 2011-08-18 シスメックス株式会社 血液中癌細胞の検出方法及びそれに用いるプログラム
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US12545960B2 (en) 2010-05-18 2026-02-10 Natera, Inc. Methods for simultaneous amplification of target loci
DE102010020785A1 (de) * 2010-05-18 2011-11-24 Siemens Aktiengesellschaft Vorrichtung und Verfahren zum Erkennen von magnetisch markierten Mikroobjekten
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
WO2011146632A1 (en) 2010-05-18 2011-11-24 Gene Security Network Inc. Methods for non-invasive prenatal ploidy calling
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
CN103608466B (zh) 2010-12-22 2020-09-18 纳特拉公司 非侵入性产前亲子鉴定方法
RU2671980C2 (ru) 2011-02-09 2018-11-08 Натера, Инк. Способы неинвазивного пренатального установления плоидности
US20120252038A1 (en) * 2011-04-01 2012-10-04 Chianese David A Steroid receptor assays
US9956281B2 (en) 2011-05-04 2018-05-01 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
EP2737317A2 (en) * 2011-07-28 2014-06-04 The Trustees Of The University Of Pennsylvania Methods for diagnosing cancer by characterization of tumor cells associated with pleural or serous fluids
ES2971646T3 (es) 2011-09-26 2024-06-06 Preanalytix Gmbh Estabilización y aislamiento de ácidos nucleicos extracelulares
ES2574956T3 (es) 2011-09-26 2016-06-23 Preanalytix Gmbh Estabilización y aislamiento de ácidos nucleicos extracelulares
US11021733B2 (en) 2011-09-26 2021-06-01 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
KR102037891B1 (ko) * 2012-03-09 2019-10-30 한국전자통신연구원 다중 분리 장치 및 혈중 암세포 분리 방법
US20150148212A1 (en) 2012-05-10 2015-05-28 Konica Minolta, Inc. Process for removing red blood cells and centrifugal tube for blood collection
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
CA2884915C (en) 2012-09-25 2022-05-17 Qiagen Gmbh Stabilisation of biological samples
US11493428B2 (en) 2013-03-15 2022-11-08 Gpb Scientific, Inc. On-chip microfluidic processing of particles
EP3608022A1 (en) 2013-03-15 2020-02-12 The Trustees of Princeton University Methods and devices for high throughput purification
US12590955B2 (en) 2013-03-15 2026-03-31 Zeon Corporation Methods and systems for processing particles
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
WO2014146782A1 (en) * 2013-03-18 2014-09-25 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
EP2976424B1 (en) 2013-03-18 2018-10-03 Qiagen GmbH Stabilisation of biological samples
US10091984B2 (en) 2013-07-24 2018-10-09 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
EP3683321B1 (en) * 2013-10-21 2021-12-08 The General Hospital Corporation Methods relating to circulating tumor cell clusters and the treatment of cancer
US10527624B2 (en) 2014-01-27 2020-01-07 Epic Sciences, Inc. Circulating tumor cell diagnostics for prostate cancer biomarkers
EP3108246B1 (en) 2014-02-21 2019-10-09 Epic Sciences, Inc. Methods for analyzing rare circulating cells
CN106132200B (zh) * 2014-03-18 2020-10-30 凯杰有限公司 胞外核酸的固定和分离
CN103940997B (zh) * 2014-03-21 2017-01-04 上海柏慧康生物科技有限公司 一种乳腺癌循环肿瘤细胞检测系统及试剂盒
US12492429B2 (en) 2014-04-21 2025-12-09 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
CA2945962C (en) 2014-04-21 2023-08-29 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
CN103980365A (zh) * 2014-06-03 2014-08-13 国家纳米科学中心 一种表面固载炭疽致死因子的磁性纳米粒子、其制备方法及用途
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
ES2872344T3 (es) * 2014-07-02 2021-11-02 Siemens Healthcare Diagnostics Inc Separación selectiva de ácidos nucleicos
EP3262195A4 (en) * 2015-02-24 2018-01-03 Siemens Healthcare Diagnostics Inc. Prefixation for increased rare cell recovery
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
CA2936167A1 (en) * 2015-07-15 2017-01-15 Streck, Inc. Method and device for stabilizing of proteins
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
JP6617495B2 (ja) * 2015-09-18 2019-12-11 東ソー株式会社 腫瘍細胞の検出方法
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
CN114457068B (zh) 2015-11-20 2025-03-14 普瑞阿那利提克斯有限公司 用于稳定细胞外核酸的已灭菌组合物的制备方法
CN105372109A (zh) * 2015-12-15 2016-03-02 苏州药明康德新药开发股份有限公司 添加稳定剂的生物基质的制备方法
EP3422848B1 (en) 2016-03-04 2025-02-12 Menarini Silicon Biosystems S.p.A. Preservation of cellular components from cells with a preservative
US11753682B2 (en) 2016-03-07 2023-09-12 Father Flanagan's Boys'Home Noninvasive molecular controls
RU2760913C2 (ru) 2016-04-15 2021-12-01 Натера, Инк. Способы выявления рака легкого
JP2017219479A (ja) 2016-06-09 2017-12-14 住友電気工業株式会社 微小粒子計測装置及び分析方法
WO2018022991A1 (en) 2016-07-29 2018-02-01 Streck, Inc. Suspension composition for hematology analysis control
WO2018067517A1 (en) 2016-10-04 2018-04-12 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
EP4556575A3 (en) 2016-11-21 2025-10-08 Bruker Spatial Biology, Inc. A method for sequencing nucleic acids
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
BR112020001091A2 (pt) 2017-08-02 2020-09-15 Sarstedt Ag & Co. Kg processo e composição para a estabilização de ácidos nucleicos livres de células
CN111065399B (zh) 2017-09-01 2023-11-28 Gpb科学有限公司 使用微流体制备治疗活性细胞的方法
CN115119829B (zh) * 2017-10-19 2024-07-12 斯特雷克股份有限公司 用于胞外囊泡的溶血和凝血调节以及稳定化的组合物
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
EP3794146B1 (en) 2018-05-14 2025-12-10 Bruker Spatial Biology, Inc. Method for identifying a predetermined nucleotide sequence
JP7334468B2 (ja) * 2018-05-29 2023-08-29 東ソー株式会社 血液試料保存剤
JP7036670B2 (ja) 2018-05-31 2022-03-15 アークレイ株式会社 血液中の稀少細胞検査、該検査ための血液処理方法及び採血管
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
CN108865976B (zh) * 2018-07-19 2022-06-28 复旦大学附属中山医院 一种离散汲取收集外泌体(exosome)的方法及试剂
CN110250159A (zh) * 2019-05-28 2019-09-20 天津中科生物科技有限公司 一种细胞保护液及其制备方法和应用
US12305235B2 (en) 2019-06-06 2025-05-20 Natera, Inc. Methods for detecting immune cell DNA and monitoring immune system
CN118284808A (zh) * 2022-03-25 2024-07-02 积水医疗株式会社 循环肿瘤细胞分离试剂盒、循环肿瘤细胞分离容器及循环肿瘤细胞的分离方法
WO2024238350A1 (en) * 2023-05-12 2024-11-21 The Children's Medical Center Corporation Single-cell regulatory multi-omics with deep mitochondrial mutation profiling (redeem)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4040785A (en) * 1976-10-18 1977-08-09 Technicon Instruments Corporation Lysable blood preservative composition
US4320111A (en) * 1977-06-14 1982-03-16 American Home Products Corporation Immunologic compositions methods of preparation and use
FR2475737A1 (fr) * 1980-02-07 1981-08-14 Pasteur Institut Perfectionnements apportes aux procedes de conservation d'hematies par lyophilisation en vue de leur utilisation dans des reactions d'hemagglutination et hematies non agglutinables spontanement obtenues par ce procede
US4404181A (en) * 1981-10-15 1983-09-13 Cambridge Chemical Products, Inc. Extended-life tissue fixative composition and method of using the same
FR2523810B1 (fr) * 1982-03-23 1988-11-25 Carpentier Alain Tissu biologique greffable et procede pour sa preparation
FR2528848A1 (fr) * 1982-06-16 1983-12-23 Sanofi Sa Nouveau derive de thieno-pyridone, son procede de preparation et son application therapeutique
EP0156537A3 (en) * 1984-03-02 1987-05-13 Board Of Regents University Of Texas System Biological magnetic fluids
US4654312A (en) * 1984-05-14 1987-03-31 Becton, Dickinson And Company Lysing agent for analysis of peripheral blood cells
US4788139A (en) * 1987-08-06 1988-11-29 Streck Laboratories, Inc. Platelet aggregation reagent, reagent container and method of determining platelet aggregation in EDTA-anticoagulated blood
US5385707A (en) * 1988-12-28 1995-01-31 Stefan Miltenyi Metal matrices for use in high gradient magnetic separation of biological materials and method for coating the same
US5698271A (en) * 1989-08-22 1997-12-16 Immunivest Corporation Methods for the manufacture of magnetically responsive particles
US5849517A (en) * 1991-05-08 1998-12-15 Streck Laboratories, Inc. Method and composition for preserving antigens and nucleic acids and process for utilizing cytological material produced by same
EP0627879A1 (en) * 1991-09-20 1994-12-14 CAMIENER, Gerald, W. Methods and compositions with aldehyde stabilizing solution
EP0685994B1 (en) * 1993-02-25 2007-03-21 Abbott Laboratories Multipurpose reagent system for rapid lysis of whole blood samples
US6190870B1 (en) * 1995-08-28 2001-02-20 Amcell Corporation Efficient enrichment and detection of disseminated tumor cells
GB2313288B (en) * 1996-05-24 2000-07-12 North Gen Hospital Nhs Trust Specimen collection fluid
US6197523B1 (en) * 1997-11-24 2001-03-06 Robert A. Levine Method for the detection, identification, enumeration and confirmation of circulating cancer and/or hematologic progenitor cells in whole blood
US6670197B2 (en) * 1997-11-24 2003-12-30 David L. Rimm Method for assaying whole blood for the presence or absence of circulating cancer or other target cell fragments
BR9907852A (pt) * 1998-02-12 2000-10-24 Immunivest Corp Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes
US6960449B2 (en) * 1999-02-10 2005-11-01 Cell Works Diagnostics, Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
US6653129B1 (en) * 1999-09-13 2003-11-25 The Regents Of The University Of Colorado Method for isolation of cells from a solution
WO2003019141A2 (en) * 2001-08-23 2003-03-06 Immunivest Corporation Analysis of circulating tumor cells, fragments, and debris

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079212A1 (en) * 2015-11-04 2017-05-11 Axon Dx, Llc Cell detection, capture, analysis, aggregation, and output methods and apparatus

Also Published As

Publication number Publication date
KR20040030984A (ko) 2004-04-09
CA2457894A1 (en) 2003-03-06
EP1425383A2 (en) 2004-06-09
EP1425294A4 (en) 2005-11-16
EP1425294B1 (en) 2008-07-16
CN1596265A (zh) 2005-03-16
CA2457891A1 (en) 2003-03-06
WO2003018757A3 (en) 2003-09-12
CA2457891C (en) 2019-10-01
IL160209A0 (en) 2004-07-25
ATE401574T1 (de) 2008-08-15
CN1571634A (zh) 2005-01-26
AU2009200013A1 (en) 2009-02-05
EP1425294A2 (en) 2004-06-09
WO2003019141A3 (en) 2004-04-01
KR20040053115A (ko) 2004-06-23
JP2005502863A (ja) 2005-01-27
AU2009200013B2 (en) 2012-03-08
IL160210A0 (en) 2004-07-25
AU2008288601B2 (en) 2012-05-31
WO2003018757A2 (en) 2003-03-06
BR0212125A (pt) 2005-06-28
DE60227678D1 (de) 2008-08-28
JP2009109514A (ja) 2009-05-21
EP1425383A4 (en) 2005-11-09
AU2008288601A1 (en) 2009-04-02
EP1425294B2 (en) 2012-12-12
JP2005501236A (ja) 2005-01-13
WO2003019141A2 (en) 2003-03-06
BR0212124A (pt) 2004-07-20

Similar Documents

Publication Publication Date Title
CA2457894C (en) Analysis of circulating tumor cells, fragments, and debris
US7863012B2 (en) Analysis of circulating tumor cells, fragments, and debris
EP2628008B1 (en) Methods and kits for the detection of circulating tumor cells in pancreatic patients using polyspecific capture and cocktail detection reagents
CA2587765A1 (en) Magnetic enrichment of circulating cells, fragments and debris for enabling hts proteomics and genomics in disease detection
US7901950B2 (en) Method for assessing disease states by profile analysis of isolated circulating endothelial cells
AU2008249153B2 (en) Methods and reagents for the rapid and efficient isolation of circulating cancer cells
ES2357101T3 (es) Celulas marcadas para su uso como control funcional interno en ensayos de detección de celulas raras.
US20090191535A1 (en) Method of assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells
JP5548890B2 (ja) 細胞の画像を格付けするための方法
EP1861509A2 (en) A method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells
WO2006041453A1 (en) Circulating tumor cells (ctc’s): apoptotic assessment in prostate cancer patients
Rao et al. Analysis of circulating tumor cells, fragments, and debris
AU2002326741A1 (en) Analysis of circulating tumor cells, fragments, and debris
WO2006020936A2 (en) A method for assessing disease states by profile analysis of isolated circulating endothelial cells
WO2006130737A1 (en) A method for assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells
Hong et al. Use of Anti-Phosphohistone H3 (PHH3) as a Mitosis Marker for Classifying Pulmonary Carcinoid Tumors

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831